Gilead's Compassionate Use Data Promising, But Imminent COVID-19 Treatment Shift Unlikely

Interpretation of remdesivir's compassionate use data is complicated by typical disease course of COVID-19 patients. The uncontrolled data raises hopes for positive trials but is unlikely to change current treatment protocols.

Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020
Gilead's experimental antiviral remdesivir may have helped COVID-19 patients, compassionate use data shows • Source: Shutterstock

More from Clinical Trials

More from R&D